Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers.
Journal
La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176
Informations de publication
Date de publication:
31 Oct 2020
31 Oct 2020
Historique:
received:
10
04
2020
accepted:
24
07
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Asbestos-related lung diseases are a group of heterogeneous disorders with different pathogenesis and prognosis. Very few studies investigated the BALF cell profile of asbestos exposed workers. The existence of a relationship between bronchoalveolar lavage fluid (BALF) cellular pattern and specific diagnosis and/or asbestos exposure biomarkers would allow the identification of effect biomarkers useful in the follow up of asbestos-exposed workers and in the diagnosis of asbestos-related diseases. To assess BALF cell profile in formerly asbestos-exposed workers and its relationship with asbestos fibre (amphibole and chrysotile) and asbestos body (AB) concentrations. 113 male workers formerly exposed to asbestos underwent bronchoscopy with bronchoalveolar lavage and were retrospectively enrolled. 35 of them were affected by pleural plaques and 10 were affected by asbestosis. Pulmonary functional tests (PFT), BALF cellular pattern, BALF mineralogical analysis with asbestos fibres and AB counting were performed in each patient. A statistical analysis with a multivariate linear regression model was adopted. From the statistical analysis of data a direct correlation between pack-years and BALF macrophages was found. Inversely correlation between pack-years and BALF lymphocytes was detected. There was not relationship among BALF cellular pattern, PFT values, specific diagnosis, BALF AB count or BALF asbestos fibre concentration. BALF cellular pattern does not seem to be related to asbestos exposure biomarkers like AB and asbestos fibre concentration in BALF. Instead, smoke habit can induce an increase in BALF macrophages and a decrease of BALF lymphocytes count.
Sections du résumé
BACKGROUND
BACKGROUND
Asbestos-related lung diseases are a group of heterogeneous disorders with different pathogenesis and prognosis. Very few studies investigated the BALF cell profile of asbestos exposed workers. The existence of a relationship between bronchoalveolar lavage fluid (BALF) cellular pattern and specific diagnosis and/or asbestos exposure biomarkers would allow the identification of effect biomarkers useful in the follow up of asbestos-exposed workers and in the diagnosis of asbestos-related diseases.
OBJECTIVES
OBJECTIVE
To assess BALF cell profile in formerly asbestos-exposed workers and its relationship with asbestos fibre (amphibole and chrysotile) and asbestos body (AB) concentrations.
METHODS
METHODS
113 male workers formerly exposed to asbestos underwent bronchoscopy with bronchoalveolar lavage and were retrospectively enrolled. 35 of them were affected by pleural plaques and 10 were affected by asbestosis. Pulmonary functional tests (PFT), BALF cellular pattern, BALF mineralogical analysis with asbestos fibres and AB counting were performed in each patient. A statistical analysis with a multivariate linear regression model was adopted.
RESULTS
RESULTS
From the statistical analysis of data a direct correlation between pack-years and BALF macrophages was found. Inversely correlation between pack-years and BALF lymphocytes was detected. There was not relationship among BALF cellular pattern, PFT values, specific diagnosis, BALF AB count or BALF asbestos fibre concentration.
DISCUSSION
CONCLUSIONS
BALF cellular pattern does not seem to be related to asbestos exposure biomarkers like AB and asbestos fibre concentration in BALF. Instead, smoke habit can induce an increase in BALF macrophages and a decrease of BALF lymphocytes count.
Identifiants
pubmed: 33124609
doi: 10.23749/mdl.v111i5.9170
pmc: PMC7809980
doi:
Substances chimiques
Asbestos
1332-21-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-387Références
Clin Exp Immunol. 2012 Mar;167(3):523-31
pubmed: 22288596
Eur Respir J. 2017 Dec 21;50(6):
pubmed: 29269588
Eur Respir J. 1992 Jul;5(7):776-9
pubmed: 1499699
Am J Ind Med. 1991;19(5):619-28
pubmed: 1647134
G Ital Med Lav Ergon. 2003 Apr-Jun;25(2):152-60
pubmed: 12872499
Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):400-5
pubmed: 1736749
Semin Respir Crit Care Med. 2007 Oct;28(5):504-13
pubmed: 17975778
PLoS One. 2012;7(3):e34232
pubmed: 22479573
Arch Bronconeumol. 2017 Jun;53(6):318-323
pubmed: 27914752
J Occup Environ Med. 2001 Oct;43(10):872-81
pubmed: 11665456
Ann Occup Hyg. 2007 Jul;51(5):495-500
pubmed: 17456581
Ind Health. 2018 Jun 1;56(3):249-254
pubmed: 29479016
Am Rev Respir Dis. 1990 May;141(5 Pt 2):S169-202
pubmed: 2186681
J Pharm Biomed Anal. 2019 Jan 30;163:122-129
pubmed: 30292984
Occup Environ Med. 2019 Oct;76(10):765-771
pubmed: 31331950
Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715
pubmed: 15355871
J Thorac Dis. 2017 Sep;9(Suppl 10):S996-S1010
pubmed: 29214060
Radiology. 1991 Feb;178(2):409-16
pubmed: 1987601
Med Lav. 2004 Jan-Feb;95(1):17-31
pubmed: 15112744
J Occup Health. 2009;51(3):210-22
pubmed: 19372629
Environ Health Prev Med. 2013 May;18(3):198-204
pubmed: 23463177
Occup Environ Med. 2020 May;77(5):352
pubmed: 32123033
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Am Rev Respir Dis. 1987 Nov;136(5):1219-24
pubmed: 3314616
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
Toxicol Ind Health. 2011 Oct;27(9):849-56
pubmed: 21421677
Scand J Work Environ Health. 2015 Jan;41(1):5-15
pubmed: 25299403